Pathology: mHCC - 1st line (L1); mHCC - 2nd line (L2);
| mHCC - 1st line (L1) | mHCC - 2nd line (L2) | |||
| LEAP 002, 0 | KEYNOTE-240, 2020 | KEYNOTE-394, 2022 | ||
| pembrolizumab plus lenvatinib | 1 | T1 | ||
| pembrolizumab based treatment | 1 | T1 | ||
| pembrolizumab alone | 1 | T1 | ||
| lenvatinib | 0 | T0 | ||
| placebo | 0 | T0 | T0 |